2nd Interim Overall Survival From MARIPOSA-2 presented by Sanjay Popat A trend toward an OS improvement in the Amivantamab + chemo vs chemo arm, but still not statistically significant at median 18.1 months FU and 75% OS events. Let’s wait for final analysis #ESMO24 #LCSM

MARIPOSA Ami+Lazer 1L EGFRm NSCLC: Acq resist mec in liquid Bx. Ami as expected reduced acquired MET amp and EGFR mut as bispecific EGFR/MET. Lower TP53/RB1 with ami/laz vs osimertinib means lower risk of histologic transformation with this combo upfront?#ESMO24 Benjamin Besse

#ESMO24 Lung Orals🔥 Super presentation by Benjamin Besse on mechanisms of acquired resistance to ami/laz in EGFR+ NSCLC shows potentially less RB1 loss/sclc transformation A clinically relevant outcome if confirmed clinically, one to watch #ESMOAmbassadors #ESMO24 ESMO - Eur. Oncology

#ESMO24 Importantly, very favorable safety profile, largely from sparing TRK signaling. Main toxicities include edema, AST and ALT elevation, weight gain - but none leading to discontinuation and dose reduction rate from TRAE only 8%. #ESMOAmbassadors

#ESMO24 Dr. Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ presents data on zipalertinib in NSCLC with an #EGFR exon 20 mutation post amivantamab. RR post ami 50% and including post ami and other EGFRex20 agents, RR 40%. mPFS 9.7 months. Reassuring safety profile. #ESMOAmbassadors

🚨 Join us at #ESMO24 today @ 6.30 PM, for our symposium exploring the emerging role of c-MET as a therapeutic target for ADCs in the treatment of lung and gastrointestinal cancers. Benjamin Besse Nicolas Girard , John Strickler, Eric Van Cutsem and myself! #LCSM #LungCancer

Dr. d.planchard at #ESMO24 presents phase II ENCO-BRAF study of first-line encorafenib + binimitinib in #BRAF V600E NSCLC. RR 66%, mPFS 10.9m, mOS not reached, safety shows only 3% pyrexia (no grade 3). #ESMOAmbassadors

#ESMO24🔥 Instructive & entertaining talk on the role of surgery for mesothelioma & the MARS2 trial- key criticisms, & systematic discussion by Eric Lim Next steps would be: - consider repeating MARS2? - revisit guidelines? - stop surgery #ESMOAmbassadors #ESMO24 ESMO - Eur. Oncology

Our fantastic #high5oncologyTV panel of #lungcancer experts discussing the latest data at #ESMO24 Alfredo Addeo MD Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Michael Thomas Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO Sacha Rothschild ESMO - Eur. Oncology

#ESMO24 Jonathan Spicer MD PhD with an update from CheckMate 77T (perioperative nivolumab vs placebo in resectable NSCLC). Impressive EFS in those who achieved pCR. ctDNA clearance much more likely with nivo - lack of clearance means little chance of pCR. #ESMOAmbassadors

In CM77T trial perioperative nivolumab clearance ctDNA correlates with pCR. However, half of patients with pCR do not have clearance. Poorer subgroup of patients? ctDNA clearance is not yet an « universal » biomarker for all #ESMO24

.Martin Reck updates AGEAN biomarkers and outcomes. N=283 available. ctDNA clearance associated with pCR and improved EFS. Pre surgical ctDNA clearance warrants further study as a predictive biomarker #ESMO24

Happy to have presented our findings on the transcriptomic inflammatory profiling of #NSCLC at #ESMO24 🫁 It's been a pleasure discussing our 7-gene expression analysis with you all!👩🏼‍🔬 ESMO - Eur. Oncology Hospital Clínic IDIBAPS Noemi Reguart Cristina Teixidó Ana Paula Gausà Busquets

Dr Lu presents LAURA CNS and distant PD data. Distant PD rate 16 vs 37%. 55% PET scan staging. PFS HR similar. TTDM HR=0.22. CNS PFS HR=0.17 #ESMO24 ESMO - Eur. Oncology

#ESMO24 Lung mini-orals🔥 ALINA analysis (Ph III adj alectinib in alk+ NSCLC), biomarker subgroups: - 139pts in biomarker eval populn (alectinib=99) Foundation 1CDx - DFS benefit in all EML4 variants - p53 co-mutation+ assoc with lower DFS Interesting #ESMOAmbassadors ESMO - Eur. Oncology

Can inhaled corticosteroid reduce RT induced lung damage during radical lung rt for unresectable IIIa/b?; n292; yes it can. 15% reduction in radiation pneumonitis. #ESMO24 lovely trial; practice changing #ESMO24

📽️We are live! Watch our reports from #ESMO24, for free and on demand: high5oncology.tv/meeting-covera… #high5oncologyTV Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO Sacha Rothschild joaquim bellmunt Anders Bjartell

So proud of this small contribution to this transformative trial that is going to dramatically improve so many SCLC patient's lifes! I am really grateful to everyone who gave me support in this journey. Durvalumab after Chemoradiotherapy in LS-SCLC nejm.org/doi/full/10.10…

🔜 Menos de un mes para celebrar la V edición Meet With The Professor con Sanjay Popat 📆 8 de octubre Un evento virtual que coordinan las Dras. Noemi Reguart y Enriqueta Felip INSCRÍBETE AHORA ⤵️ tacticsmd.net/actividad/v-me… #MPITT2024

A warm invite from high5md to tune into high5Oncology TV for the TOP News out of #ESMO24 by great International experts Tune in here: high5oncology.tv/meeting-covera…